This page was machine-translated and may differ from the original. View original

MediThinQ Appoints Lee Hee-yeol as Co-CEO...Accelerating Global Business Expansion

Google 우선 소스Published2026.08.11 08:39
Lee Hee-yeol (Chris Lee), Chairman of the Board and Co-CEO of MediThinQ, speaks at a strategic workshop held in July. On the right is Lim Seung-jun, Co-CEO of MediThinQ.


Accelerating Growth Through Overseas Revenue Expansion and IPO Initiatives


Medical visualization solution company MediThinQ is adopting a co-CEO system to expand into global markets and enhance corporate value.


MediThinQ announced that it has appointed Lee Hee-yeol, CEO of VentureBlic, as co-CEO and launched a co-CEO management structure to operate the company together with founder CEO Lim Seung-jun.


This personnel move is part of a strategy to accelerate overseas market penetration and corporate growth by adding global business capabilities to technology-centered management.


Co-CEO Lee Hee-yeol currently serves as Chairman of MediThinQ's Board and is a professional manager with over 30 years of management experience in the global healthcare industry.


He previously served as President of Medtronic Asia Pacific and President of operations for Greater China, Taiwan, and Hong Kong regions, and was also responsible for Asia Pacific and China operations at Bayer Healthcare. Subsequently, in 2022 he established VentureBlic, a healthcare commercialization specialist company, and has continued to support global business expansion and growth strategy initiatives.


MediThinQ explained that the co-CEO will be responsible for overseas market expansion, strategic partnership building, organizational operational enhancement, and corporate value improvement.


Co-CEO Lim Seung-jun will continue to oversee research and development (R&D), product strategy, and core business operations as before.


Through the co-CEO system, MediThinQ plans to focus on connecting technological development and product innovation to global business results.


The company announced that it is currently pursuing business operations with global healthcare companies including Medtronic, Baxter, and Sinopharm under distribution and supply contracts in major markets such as the United States and China.


Going forward, the company plans to strengthen global business execution capabilities while pursuing investment attraction and initial public offering (IPO) preparation.


CEO Lim Seung-jun stated, "We will strengthen technology and product competitiveness while accelerating the pace of global business growth."


Co-CEO Lee Hee-yeol said, "We will strengthen global business strategy and organizational execution capabilities to expand our influence in overseas markets."

본 기사에 대한 정정·반론·추후보도 청구는 보도 청구 안내를, 그간 게재된 보도문은 정정·반론보도 모아보기를 참고해 주세요.
배종인 기자
배종인 기자